Biodegradable polyurethane foam modified with 55% polyethyleneglycol as a local hemostatic agent, a pilot study.

Biodegradable polyurethane foam modified with 55% polyethyleneglycol as a local hemostatic agent, a pilot study. - Polyurethane foam as a local hemostatic agent.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31951

Enrollment

Registered

2008-12-09

Start date

2008-04-20

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stolling van humaan bloed coagulation

Interventions

The selected patients will be divided into two groups. In the first group the degree of clotformation in polyurethane foam will be compared to the degree of clotformation in Willospon (absorbable ge

Will-Pharma BV, Zwanenburg, Nederland). In the second group the degree of clotformation in polyurethane foam will be compared to the degree of clotformation in Novacol ( absorbable collagen hemosta

Bioprof BV, Moerkapelle, Nederland). Novacol and Willospon are already used as local hemostatic agents in the dentistry. Only 1 kind of foam will be tested in each socket.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients who require at least 2 extractions in 1 session

Exclusion criteria

Exclusion criteria: Patients under 18 years and immune compromised patients. Patients who use oral anticoagulant therapy.

Design outcomes

Primary

Measure	Time frame
The primary study parameter is the degree of clotformation ( concentration thrombin) in polyurethane foam in comparison with the baseline values of the blood and the concentration thrombin in Willospon and Novacol.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)